Mathias Seeliger

Title: Innovations by Mathias Seeliger in Gene Therapy

Introduction

Mathias Seeliger is a notable inventor based in Rottenburg, Germany. He has made significant contributions to the field of gene therapy, particularly in the treatment of retinal diseases. With a total of 2 patents, his work focuses on innovative solutions for conditions affecting vision.

Latest Patents

Seeliger's latest patents include groundbreaking advancements in gene therapy. The first patent addresses a polynucleotide designed for the treatment of retinal degeneration diseases, such as retinitis pigmentosa (RP). This invention encompasses a nucleic acid vector, a pharmaceutical composition, and methods for both creating the vector and treating the disease. The second patent pertains to a polynucleotide aimed at treating diseases of retinal cone cells, like achromatopsia. Similar to the first, this invention includes a nucleic acid vector, a pharmaceutical composition, and methods for treatment.

Career Highlights

Mathias Seeliger is associated with Eyeserv GmbH, where he applies his expertise in gene therapy. His work is pivotal in developing therapeutic strategies that could potentially restore vision for individuals suffering from retinal diseases.

Collaborations

Seeliger collaborates with esteemed colleagues, including Martin Biel and Stylianos Michalakis. Their combined efforts contribute to advancing research and innovation in the field of gene therapy.

Conclusion

Mathias Seeliger's contributions to gene therapy represent a significant advancement in treating retinal diseases. His innovative patents and collaborative efforts continue to pave the way for future breakthroughs in vision restoration.